Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.

Durieu I, Clements B, Fabrizzi B, Mall MA, McKone E, Ramsey B, Tullis E, Taylor-Cousar JL, van der Meer R, Bachman E, Chin A, Conner S, Jennings M, Weinstock T, Colombo C, Robinson P

Open source

DOI: 10.1164/rccm.202411-2312oc
Published: 2025 Oct
Container: American journal of respiratory and critical care medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1164/rccm.202411-2312oc,
  title = {Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.},
  author = {Durieu I and Clements B and Fabrizzi B and Mall MA and McKone E and Ramsey B and Tullis E and Taylor-Cousar JL and van der Meer R and Bachman E and Chin A and Conner S and Jennings M and Weinstock T and Colombo C and Robinson P},
  year = {2025},
  journal = {American journal of respiratory and critical care medicine},
  doi = {10.1164/rccm.202411-2312oc},
  url = {https://doi.org/10.1164/rccm.202411-2312oc}
}

RIS

TY  - JOUR
TI  - Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.
AU  - Durieu I
AU  - Clements B
AU  - Fabrizzi B
AU  - Mall MA
AU  - McKone E
AU  - Ramsey B
AU  - Tullis E
AU  - Taylor-Cousar JL
AU  - van der Meer R
AU  - Bachman E
AU  - Chin A
AU  - Conner S
AU  - Jennings M
AU  - Weinstock T
AU  - Colombo C
AU  - Robinson P
PY  - 2025
JO  - American journal of respiratory and critical care medicine
DO  - 10.1164/rccm.202411-2312oc
UR  - https://doi.org/10.1164/rccm.202411-2312oc
ER  -

APA

I, D., B, C., B, F., MA, M., E, M., B, R., E, T., JL, T., R, V. D. M., E, B., A, C., S, C., M, J., T, W., C, C., & P, R. (2025). Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial.. American journal of respiratory and critical care medicine. https://doi.org/10.1164/rccm.202411-2312oc

Source records

pubmed · retrieved 2026-09-26T07:27:44.025Z